Limits...
Silibinin inhibits accumulation of myeloid-derived suppressor cells and tumor growth of murine breast cancer.

Forghani P, Khorramizadeh MR, Waller EK - Cancer Med (2014)

Bottom Line: Silibinin, a natural flavonoid from the seeds of milk thistle, has been developed as an anti-inflammatory agent and supportive care agent to reduce the toxicity of cancer chemotherapy.The effects of silibinin on 4T1 cell viability in vitro were measured by BLI.The antitumor activity of silibinin requires an intact host immune system and is associated with decreased accumulation of blood and tumor-associated MDSCs.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathobiology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.

Show MeSH

Related in: MedlinePlus

Silibinin treatment decreased tumor volume and increased survival in mice with 4T1 breast cancer tumors. BALB/c mice were inoculated with 1 × 106 4T1-luciferase tumor cells and then treated with silibinin by gavage three times per week starting on day 14 (150 mg/kg). (A) Pseudo color luminescent images represent increasing emitted light and tumor volumes (blue, green, yellow, and red from least to most intense, respectively). Representative silibinin-treated versus vehicle-treated mice. In vivo visualization of 4T1 breast tumor volume at day 28 after tumor inoculation. (B) Total flux detected in individual mice after silibinin treatment on day 28 after tumor inoculation comparing silibinin-treated and control groups. Total flux collected in an ROI following a 30-sec exposure time. (C) Survival of silibinin-treated BALB/c mice versus vehicle-treated BALB/c mice. The times of gavage are shown as arrows. Data are compiled from three separate experiments (n = 4–5 per group).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3987072&req=5

fig01: Silibinin treatment decreased tumor volume and increased survival in mice with 4T1 breast cancer tumors. BALB/c mice were inoculated with 1 × 106 4T1-luciferase tumor cells and then treated with silibinin by gavage three times per week starting on day 14 (150 mg/kg). (A) Pseudo color luminescent images represent increasing emitted light and tumor volumes (blue, green, yellow, and red from least to most intense, respectively). Representative silibinin-treated versus vehicle-treated mice. In vivo visualization of 4T1 breast tumor volume at day 28 after tumor inoculation. (B) Total flux detected in individual mice after silibinin treatment on day 28 after tumor inoculation comparing silibinin-treated and control groups. Total flux collected in an ROI following a 30-sec exposure time. (C) Survival of silibinin-treated BALB/c mice versus vehicle-treated BALB/c mice. The times of gavage are shown as arrows. Data are compiled from three separate experiments (n = 4–5 per group).

Mentions: To determine whether silibinin inhibits 4T1 breast tumor growth, mice were inoculated subcutaneously with 4T1-luc cells in the left flank. Although tumors were not palpable until day 7 post implantation, bioluminescent signals were detected from day 0 (data not shown). Two weeks after tumor inoculation, groups of mice were treated with vehicle (control) or silibinin (150 mg/kg) every other day by gavage. Comparing silibinin-treated mice versus vehicle-treated mice, a significant decrease in total flux was seen following six treatments over 14 days. (Fig. 1A and B; P < 0.05). Animals were then followed up for survival following the 14 days of treatment with silibinin or vehicle. Silibinin treatment was associated with a significant prolongation of survival compared with vehicle-treated controls, with a median survival of 34 days versus 25 days, respectively. (Fig. 1C; P < 0.05). Physical measurement of tumor volume with calipers confirmed difference seen by BLI (data not shown).


Silibinin inhibits accumulation of myeloid-derived suppressor cells and tumor growth of murine breast cancer.

Forghani P, Khorramizadeh MR, Waller EK - Cancer Med (2014)

Silibinin treatment decreased tumor volume and increased survival in mice with 4T1 breast cancer tumors. BALB/c mice were inoculated with 1 × 106 4T1-luciferase tumor cells and then treated with silibinin by gavage three times per week starting on day 14 (150 mg/kg). (A) Pseudo color luminescent images represent increasing emitted light and tumor volumes (blue, green, yellow, and red from least to most intense, respectively). Representative silibinin-treated versus vehicle-treated mice. In vivo visualization of 4T1 breast tumor volume at day 28 after tumor inoculation. (B) Total flux detected in individual mice after silibinin treatment on day 28 after tumor inoculation comparing silibinin-treated and control groups. Total flux collected in an ROI following a 30-sec exposure time. (C) Survival of silibinin-treated BALB/c mice versus vehicle-treated BALB/c mice. The times of gavage are shown as arrows. Data are compiled from three separate experiments (n = 4–5 per group).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3987072&req=5

fig01: Silibinin treatment decreased tumor volume and increased survival in mice with 4T1 breast cancer tumors. BALB/c mice were inoculated with 1 × 106 4T1-luciferase tumor cells and then treated with silibinin by gavage three times per week starting on day 14 (150 mg/kg). (A) Pseudo color luminescent images represent increasing emitted light and tumor volumes (blue, green, yellow, and red from least to most intense, respectively). Representative silibinin-treated versus vehicle-treated mice. In vivo visualization of 4T1 breast tumor volume at day 28 after tumor inoculation. (B) Total flux detected in individual mice after silibinin treatment on day 28 after tumor inoculation comparing silibinin-treated and control groups. Total flux collected in an ROI following a 30-sec exposure time. (C) Survival of silibinin-treated BALB/c mice versus vehicle-treated BALB/c mice. The times of gavage are shown as arrows. Data are compiled from three separate experiments (n = 4–5 per group).
Mentions: To determine whether silibinin inhibits 4T1 breast tumor growth, mice were inoculated subcutaneously with 4T1-luc cells in the left flank. Although tumors were not palpable until day 7 post implantation, bioluminescent signals were detected from day 0 (data not shown). Two weeks after tumor inoculation, groups of mice were treated with vehicle (control) or silibinin (150 mg/kg) every other day by gavage. Comparing silibinin-treated mice versus vehicle-treated mice, a significant decrease in total flux was seen following six treatments over 14 days. (Fig. 1A and B; P < 0.05). Animals were then followed up for survival following the 14 days of treatment with silibinin or vehicle. Silibinin treatment was associated with a significant prolongation of survival compared with vehicle-treated controls, with a median survival of 34 days versus 25 days, respectively. (Fig. 1C; P < 0.05). Physical measurement of tumor volume with calipers confirmed difference seen by BLI (data not shown).

Bottom Line: Silibinin, a natural flavonoid from the seeds of milk thistle, has been developed as an anti-inflammatory agent and supportive care agent to reduce the toxicity of cancer chemotherapy.The effects of silibinin on 4T1 cell viability in vitro were measured by BLI.The antitumor activity of silibinin requires an intact host immune system and is associated with decreased accumulation of blood and tumor-associated MDSCs.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathobiology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.

Show MeSH
Related in: MedlinePlus